Sofie Kämereit

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Endoplasmic Reticulum Stress

Acute Lymphoblastic Leukemia

Top Venues

Science translational medicine

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Latifa Zekri, Ilona Hagelstein, Melanie Märklin, Boris Klimovich, Mary Christie, Cornelia Lindner, Sofie Kämereit, Nisha Prakash, Stefanie Müller, Sophie Stotz, Andreas Maurer, Carsten L Greve, Bastian Schmied, Daniel Atar, Hans-Georg Rammensee, Gundram Jung, Helmut R Salih
Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies. Science translational medicine 16 (737) (2024)
Latifa Zekri, Ilona Hagelstein, Melanie Märklin, Boris Klimovich, Mary Christie, Cornelia Lindner, Sofie Kämereit, Nisha Prakash, Stefanie Müller, Sophie Stotz, Andreas Maurer, Carsten L Greve, Bastian Schmied, Daniel Atar, Hans-Georg Rammensee, Gundram Jung, Helmut R Salih
Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies. Science translational medicine 16 (737) (2024)
Latifa Zekri, Ilona Hagelstein, Melanie Märklin, Boris Klimovich, Mary Christie, Cornelia Lindner, Sofie Kämereit, Nisha Prakash, Stefanie Müller, Sophie Stotz, Andreas Maurer, Carsten L Greve, Bastian Schmied, Daniel Atar, Hans-Georg Rammensee, Gundram Jung, Helmut R Salih
Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies. Science translational medicine 16 (737) (2024)
Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, Sofie Kämereit, Eftychia Chatziioannou, Simon Riel, Tobias Sinnberg, Birgit Schittek
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo . Cancer research communications 3 (9) (2023)